The 12-Month Post-Deal Review: Did the Acquisition Thesis Hold?

Twelve months after close, most deal teams sit on a pile of reporting: monthly packs, KPI dashboards, board summaries. What they usually do not have is a single document that answers the question the investment committee actually asked when it approved the deal: were the assumptions we underwrote correct? The 12-month post-deal review is that document. It is a scheduled governance event, held once at the one-year mark, in which each load-bearing claim of the original acquisition thesis is laid against observed outcomes and given a verdict with a source attached. It is a thesis audit, not a performance review and not a forecast revision.

The distinction matters because the three exercises answer different questions and produce different documents. A performance review grades the management team against budget. A forecast revision updates the outlook for the remaining hold period. A thesis audit grades the underwriting itself: which claims proved correct, which failed, and what drove the gap. Conflating them is how firms end up with rich reporting and no institutional memory of what they learned from a deal.

A governance event, not a tracking discipline

The review is also distinct from the continuous measurement of individual value creation levers during the holding period. Lever tracking, the discipline covered in the sibling article on VCP evidence tracking, is ongoing: it watches whether specific initiatives, such as pricing actions or cross-sell programs, are delivering month by month. The 12-month thesis review is a single retrospective checkpoint. It does not ask whether a lever is on track this quarter; it asks whether the fundamental assumptions behind the deal, the ones that justified the price, held. One is operational monitoring. The other is a governance artifact.

That distinction determines ownership and scope. Lever tracking typically sits with the portfolio company's finance function and the operating partner responsible for the workstreams. The thesis review belongs to the deal team and the investment committee, because its subject is the firm's own judgment, not the company's execution. And the questions it answers are different in kind: not "is the plan on track?" but "would we underwrite this deal the same way again, knowing what we now know?"

The need for a separate artifact is well documented. Plante Moran's analysis of post-acquisition reporting finds that reporting often improves materially after close, with shorter close cycles and more sophisticated dashboards, while the connection between day-to-day reporting and the original investment thesis weakens, leaving sponsors unable to see whether key elements of the thesis are quietly drifting off course.^[1] A scheduled thesis review exists precisely to close that gap: it forces the underwriting assumptions back onto the table once a year, in their original wording, against evidence.

• It is: a one-time, scheduled audit of the original deal thesis, claim by claim, with a source and verdict per claim.
• It is not: a management performance review, a budget variance analysis, or a reforecast of the remaining hold period.
• It is not: the continuous tracking of value creation levers during the hold, which is a separate, ongoing discipline.
• Its owner: the deal team and investment committee, not the portfolio company's finance function.

The timing is not arbitrary. The first year after close is when the patterns that determine the outcome are set. Crowe's analysis of post-close pitfalls notes that the first year sets the tone for how the company will make decisions, allocate capital, pursue growth, and manage reporting expectations, and that misalignment early in the hold period makes it harder to deliver on the investment thesis.^[2] A thesis review at month 12 reads the evidence that first year produced, while the decisions that shaped it are still recent enough to be examined honestly.

The stakes are high because the base rates are unforgiving. Study after study puts the failure rate of mergers and acquisitions somewhere between 70% and 90%, according to Harvard Business Review.^[3] McKinsey identifies the winner's curse as the core problem: the average acquirer materially overestimates the synergies a merger will yield.^[4] Most deals disappoint for reasons that were visible in the assumptions, not in the execution. A review that surfaces those assumption failures early is one of the few levers a firm has against those base rates.

Early enough to matter, late enough to know

Month 12 is the first point at which there is enough operating evidence to judge the load-bearing assumptions. Customer behaviour, pricing power, synergy capture, and integration friction all have at least a few quarters of real data behind them. Yet the review still lands early enough to change course: the remaining hold period is typically four or more years, so a thesis that is failing can be re-underwritten, a value creation plan can be reset, and exit timing can be revisited while those decisions still carry value. Wait until year three and the review becomes an autopsy; at month 12 it is still a steering instrument.

There is also a governance logic to fixing the checkpoint. Crowe warns that sponsors who do not proactively assess changing market conditions risk pursuing strategies that no longer match the company's capabilities or the most likely exit path.^[2] A scheduled review at a fixed month removes the discretion over whether the examination happens at all. Without a hard date, thesis reviews drift into the same category as post-deal retrospectives generally acknowledged but rarely held.

• Month 12: first full year of operating evidence on the load-bearing assumptions.
• Remaining hold period: still long enough for a failed thesis to be re-underwritten and the plan reset.
• Fixed date: removes discretion over whether the review happens, and aligns with annual board and LP reporting cycles.

The review artifact is a structured document with one row per thesis claim. Its power comes from its discipline: the original claims are quoted as written at underwriting, not paraphrased from memory, and each observed outcome carries a source. The document is therefore auditable by someone who was not in the room, which is exactly what makes it a governance artifact rather than a narrative.

Extracting the load-bearing claims

Start from the original deal model and investment memo. Not every assumption deserves a row; the review is about the load-bearing ones. M&A Science offers a clean test for identifying them: for each value driver, ask "if this turned out to be false, would I still do the deal at the same price?" If the answer is yes, it is a nice-to-have, not a value driver.^[5] The same test, run in reverse at month 12, tells you which claims the review must grade: the ones where a false answer would have changed the price you paid.

In practice, a mid-market buyout thesis yields somewhere between five and ten such claims: the revenue growth assumption, the pricing headroom, the synergy figure, the churn behaviour of the core customer base, the integration timeline. Each becomes a row in the artifact.

One row per claim, with a source

Each row contains three elements: the original claim as written at underwriting, the observed outcome at month 12, and a source for that outcome. The source requirement is what separates a thesis review from a memo written after the fact. Acceptable sources range from ERP and CRM extracts to customer interviews, churn cohorts, board packs, and third-party market data. The standard is simple: every verdict must be traceable to evidence a third party could inspect, rather than argued from recollection.

The illustrative rows above show the shape; the actual figures in your artifact will come from your own systems. What matters is the structure: the claim is quoted verbatim from the underwriting memo, the outcome is a measured fact, and the source is a document or dataset someone else could pull. Where a claim cannot be sourced, that is itself a finding: it usually means the assumption was never made measurable at underwriting, which is a lesson for the next deal.

Once the claims are mapped to outcomes, each row receives a verdict. Three categories are enough. "Held" means the observed outcome matches the claim within the tolerance a reasonable underwriter would have accepted. "Partially held" means the direction was right but the magnitude or timing fell short. "Failed" means the assumption did not materialise in any meaningful sense. The evidence bar should be set before the review, not negotiated row by row in the meeting: a verdict of "held" requires a source showing the outcome at or above the underwritten level, and "partially held" requires a source showing a shortfall that is quantified rather than characterised.

Attributing the gap

Every claim that did not fully hold gets a cause attribution, and the discipline is to choose among exactly three: the assumption was wrong at underwriting, execution fell short, or the market moved. The attribution is not a blame exercise; it is the analytical core of the review. A failed pricing assumption caused by a competitor's discounting is a market event. The same failure caused by an untested belief about customer loyalty is an underwriting error. The two lead to different changes in how the firm underwrites the next deal, which is the entire point of the artifact.

The verdict discipline also guards against the failure mode described above: reporting that appears comprehensive while the thesis quietly drifts.^[1] A monthly pack can look thorough while never once asking whether the underwriting assumptions still hold. The claim-by-claim verdict forces that question onto the agenda in a form that cannot be answered with a variance explanation.

• Held: outcome matches the claim within a reasonable underwriting tolerance, evidenced by a source.
• Partially held: direction confirmed, magnitude or timing short, with the shortfall quantified.
• Failed: the assumption did not materialise, evidenced by a source.
• Every non-held claim carries one of three causes: wrong at underwriting, execution shortfall, or market shift.

Governance of the review matters as much as its content. The natural owner is an operating partner or deal team lead with independence from portfolio management: someone close enough to the deal to know the thesis, but not the person responsible for the value creation plan's day-to-day delivery. Management input is essential, since the team closest to the customers and the systems holds much of the evidence, but management does not grade its own thesis. The firm underwrote the deal; the firm audits it.

Feeding IC reporting and LP updates

The review's outputs flow into two governance channels. Internally, it becomes an investment committee report: the IC that approved the deal receives a claim-by-claim accounting of what held and what did not, with sources. Externally, its conclusions feed LP updates. The reporting context is tightening: ILPA released its updated Reporting Template and a new Performance Template in January 2025 as part of its Quarterly Reporting Standards Initiative, aimed at greater standardisation, transparency and comparability in private funds reporting.^[6] LPs increasingly expect GPs to demonstrate not just performance numbers but an understanding of why portfolio companies performed as they did. A structured thesis review is the raw material for that narrative.

Feeding the next underwriting decision

The third destination is forward-looking. Aggregated across deals, the review artifacts show which assumption types the firm systematically gets wrong: if pricing-power claims fail in three consecutive reviews while churn claims hold, that pattern is underwriting insight no amount of market study will produce. That pattern, not any single deal's verdict, is where the review earns its cost.

• Owner: operating partner or deal team lead, independent of portfolio management.
• Management provides evidence and input; it does not assign the verdicts.
• Outputs: IC report, LP update narrative, and an aggregated input to future underwriting.

Some reviews will conclude that the thesis was materially wrong: not a claim or two off, but the core logic of the deal invalidated. This is the escalation path the artifact exists to trigger, and it should be planned for rather than improvised. The first step is to re-underwrite the remaining hold period from current evidence rather than the original model. The original deal model served its purpose at entry; continuing to steer by it after its core assumptions have failed is not discipline, it is anchoring. Re-underwriting means rebuilding the equity story from what is now known: current customer behaviour, actual cost structure, demonstrated synergy capture.

The second step is to reset or replace the value creation plan, and to revisit exit timing and path with the investment committee, using the claim-by-claim evidence as the shared factual base. A thesis that failed on market assumptions points toward an earlier or different exit route; one that failed on execution may justify a management change and a longer hold. The verdict table is what makes that conversation evidence-led rather than positional.

More common than exceptional

Firms should not treat a materially wrong thesis as a taboo. McKinsey research reported by Alternatives Watch finds that private equity firms are increasingly reexamining investments after acquisition, as extended hold periods, slower exits, and changing market conditions prompt sponsors to challenge the assumptions behind their original deal theses.^[7] McKinsey's own work on reunderwriting describes the best-performing PE firms as those that build on deal diligence in a disciplined way throughout the hold period, revisiting and retuning their exit options and equity stories rather than treating entry analysis as final.^[8] The 12-month review is the scheduled, documented version of that second look.

1. Re-underwrite the remaining hold period from current evidence, not the original model.
2. Reset or replace the value creation plan based on the claim-by-claim verdicts.
3. Revisit exit timing and path with the investment committee, using the artifact as the shared evidence base.
4. Document the decision and its rationale in the same artifact, so the record stays complete.

The final step closes the loop. A review that ends in a filing has been an exercise; a review that changes the next deal has been an education. The findings should be codified into the firm's own underwriting: which claim types failed most often, which sources proved most predictive, which diligence questions would have caught the gaps. McKinsey's advice on effective deal teams is to codify experiences rather than let them leave with the deal team.^[4] The 12-month artifact is precisely that codification, produced while the evidence is fresh and sourced.

From one deal to the firm's underwriting

Concretely, the review should update three things: screening criteria, so the firm stops buying into assumption types it repeatedly gets wrong; diligence checklists, so the questions that would have caught this deal's failures are asked on the next one; and pricing discipline, so claims that failed historically are underwritten with wider margins or explicit contingencies. Aggregated over a fund cycle, these updates compound into a genuine underwriting edge, which is the return on the governance effort the review requires.

The same logic applies to how firms adopt new tooling. A firm piloting an AI strategy platform can back-test it on completed deals: run the platform against a past deal's documents and thesis, and score its output against what the firm now knows from the 12-month review. Decisity's guide to piloting an AI strategy platform through the back-test sets out exactly this protocol, scoring AI-assisted analysis against the conclusions the firm actually reached. The 12-month thesis review and the platform back-test are the same intellectual move, applied to different objects: hold the original judgment against the evidence, claim by claim, and learn from the gap. Firms that run both build a repeatable discipline: the review teaches them about their deals, and the back-test teaches them whether their tools can be trusted with the next one.

Related reading in this series: Tracking Value-Creation Plan Delivery Against a Frozen Baseline and Documenting Deal Structure Decisions for Board or IC Review.

• Plante Moran: When post-acquisition reporting misses the investment thesis (2026)
• Crowe: Four post-close pitfalls private equity firms should avoid
• Harvard Business Review: The New M&A Playbook
• McKinsey & Company: Where mergers go wrong
• MAScience: Validating your M&A deal thesis — four key steps
• ILPA: Updated reporting template and performance measurement standards
• Alternatives Watch: McKinsey — PE firms revisit investment theses for longer hold periods (2026)
• McKinsey & Company: The second look — an adaptive approach to re-underwriting